Genosaber is a pioneering brand in the field of precision medicine, especially focused on innovative diagnostic technologies for cancer. They are dedicated to providing a comprehensive solution for liquid biopsy, a non-invasive method to detect and monitor tumors. Genosaber is involved in the development, production, sales, and clinical testing services of various cancer diagnostic tests, as well as offering a cloud-based tumor data platform.

Founded in November 2010 in Zhangjiang Pharma Valley, Shanghai, Genosaber has received strong support from various government departments, including central and state-level organizations such as the US Congress, Chinese Academy of Medical Sciences, Mayo Clinic, and Shanghai Cancer Hospital. They have been recognized for their contributions through numerous national patents and academic awards. With their cutting-edge technology, Genosaber produced the Positively Circulating Tumor Cell Detection Kit in January 2016, which received the highest level of regulatory approval from the National Medical Products Administration.

This test has undergone extensive clinical validation, providing reliable support for precise tumor treatment, helping patients extend their survival and improve their quality of life. For more information about Genosaber, their website provides comprehensive navigation, technical support, and privacy policy details. Copyright © 2020 GENOSABER.

All rights reserved. Registration Number: Shanghai ICP Preparation 19045550-1